Novel Drug Delivery Systems (NDDS) Market in Cancer Therapy Analysis by Workflow and End User to 2014-2025
The Global Novel Drug Delivery Systems (NDDS) In Cancer Therapy Market is expected to reach USD 26.61 billion by 2025, according to a new report by Hexa Reports. The market is primarily driven by global rise in incidence of cancer, increase in research activities.
The Global Novel Drug Delivery Systems (NDDS) In Cancer Therapy Market is expected to reach USD 26.61 billion by 2025, according to a new report by Hexa Reports. The market is primarily driven by global rise in incidence of cancer, increase in research activities.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Novel</strong> <strong>Drug</strong> <strong>Delivery</strong> <strong>Systems</strong> (<strong>NDDS</strong>) <strong>Market</strong> <strong>in</strong> <strong>Cancer</strong> <strong>Therapy</strong><br />
<strong>Analysis</strong> <strong>by</strong> <strong>Workflow</strong> <strong>and</strong> <strong>End</strong> <strong>User</strong> <strong>to</strong> <strong>2014</strong>-<strong>2025</strong><br />
“The Global <strong>Novel</strong> <strong>Drug</strong> <strong>Delivery</strong> <strong>Systems</strong> (<strong>NDDS</strong>) In <strong>Cancer</strong> <strong>Therapy</strong> <strong>Market</strong><br />
is expected <strong>to</strong> reach USD 26.61 billion <strong>by</strong> <strong>2025</strong>, accord<strong>in</strong>g <strong>to</strong> a new report <strong>by</strong><br />
Hexa Reports. The market is primarily driven <strong>by</strong> global rise <strong>in</strong> <strong>in</strong>cidence of<br />
cancer, <strong>in</strong>crease <strong>in</strong> research activities.”<br />
The Global <strong>Novel</strong> <strong>Drug</strong> <strong>Delivery</strong> <strong>Systems</strong> (<strong>NDDS</strong>) In <strong>Cancer</strong> <strong>Therapy</strong> <strong>Market</strong> is expected <strong>to</strong> reach USD 26.61<br />
billion <strong>by</strong> <strong>2025</strong>, accord<strong>in</strong>g <strong>to</strong> a new report <strong>by</strong> Hexa Reports. The market is primarily driven <strong>by</strong> global rise <strong>in</strong><br />
<strong>in</strong>cidence of cancer, <strong>in</strong>crease <strong>in</strong> research activities for develop<strong>in</strong>g novel drug delivery technologies, <strong>and</strong><br />
availability of research fund<strong>in</strong>g for ongo<strong>in</strong>g projects.<br />
Many key players <strong>in</strong> this market are <strong>in</strong>vest<strong>in</strong>g <strong>in</strong> R&D of novel <strong>and</strong> advanced products. This can also be<br />
attributed <strong>to</strong> <strong>in</strong>crease <strong>in</strong> patent expirations. For <strong>in</strong>stance, the R&D expenditure of Celgene Corporation<br />
<strong>in</strong>creased from USD 3,697.3 million <strong>in</strong> 2015 <strong>to</strong> USD 4,470.1 million <strong>in</strong> 2016. Increase <strong>in</strong> R&D spend<strong>in</strong>g was<br />
directed <strong>to</strong>ward enhanc<strong>in</strong>g product pipel<strong>in</strong>e <strong>and</strong> for regula<strong>to</strong>ry approvals of new products.<br />
Request A Sample copy of This Report @ http://www.hexareports.com/report/novel-drug-deliverysystems-<strong>in</strong>-cancer-therapy-market/request-sample<br />
In addition, rise <strong>in</strong> healthcare expenditure for diagnosis <strong>and</strong> treatment of cancer <strong>and</strong> awareness about<br />
alternative therapies are expected <strong>to</strong> boost market growth. Improvement <strong>in</strong> healthcare <strong>in</strong>frastructure <strong>in</strong><br />
develop<strong>in</strong>g nations <strong>and</strong> <strong>in</strong>crease <strong>in</strong> awareness about new treatment methods for cancer are also anticipated<br />
<strong>to</strong> propel the market dur<strong>in</strong>g the forecast period.<br />
Follow Us:
North America held the largest market share <strong>in</strong> 2016. Local presence of a large number of manufacturers,<br />
ongo<strong>in</strong>g regula<strong>to</strong>ry approvals for new drugs, <strong>and</strong> availability of research fund<strong>in</strong>g for new methods of<br />
treatment for this disorder are key fac<strong>to</strong>rs that can be attributed <strong>to</strong> this region's dom<strong>in</strong>ance <strong>in</strong> the global<br />
market. However, Asia Pacific is expected <strong>to</strong> grow at the highest rate dur<strong>in</strong>g the forecast period. This can be<br />
attributed <strong>to</strong> rise <strong>in</strong> <strong>in</strong>itiatives that boost cancer research projects, <strong>in</strong>crease <strong>in</strong> healthcare expenditure for<br />
cancer therapy, improvement <strong>in</strong> healthcare <strong>in</strong>frastructure, large geriatric population base, <strong>and</strong> rise <strong>in</strong><br />
awareness ow<strong>in</strong>g <strong>to</strong> medical conferences <strong>and</strong> meet<strong>in</strong>gs <strong>in</strong> the region.<br />
Browse Detail Report With TOC @<br />
http://www.hexareports.com/report/novel-drug-delivery-systems-<strong>in</strong>-cancer-therapy-market<br />
Further key f<strong>in</strong>d<strong>in</strong>gs from the report suggest:<br />
The nanoparticles segment held the largest revenue share <strong>in</strong> 2016 due <strong>to</strong> <strong>in</strong>crease <strong>in</strong> fund<strong>in</strong>g for<br />
research us<strong>in</strong>g these particles<br />
The embolization particles segment is expected <strong>to</strong> grow at the highest rate dur<strong>in</strong>g the forecast period<br />
ow<strong>in</strong>g <strong>to</strong> higher precision rate <strong>and</strong> accurate drug delivery<br />
North America dom<strong>in</strong>ated the global market due <strong>to</strong> presence of a large number of cancer patients <strong>and</strong><br />
favorable reimbursement scenario<br />
Some of the key players are Celgene Corporation; Teva Pharmaceutical Industries, Ltd.; GALEN; Shire;<br />
Johnson & Johnson Services, Inc.; <strong>and</strong> Spectrum Pharmaceuticals, Inc.<br />
Table of Contents<br />
Chapter 1 Research Methodology<br />
Chapter 2 Executive Summary<br />
Chapter 3 <strong>Novel</strong> <strong>Drug</strong> <strong>Delivery</strong> <strong>Systems</strong> (<strong>NDDS</strong>) <strong>in</strong> <strong>Cancer</strong> <strong>Therapy</strong> <strong>Market</strong> Variables, Trends & Scope<br />
Chapter 4 <strong>Novel</strong> <strong>Drug</strong> <strong>Delivery</strong> <strong>Systems</strong> (<strong>NDDS</strong>) <strong>in</strong> <strong>Cancer</strong> <strong>Therapy</strong> <strong>Market</strong>: Product Estimates & Trend<br />
<strong>Analysis</strong><br />
Chapter 5 <strong>Novel</strong> <strong>Drug</strong> <strong>Delivery</strong> <strong>Systems</strong> (<strong>NDDS</strong>) <strong>in</strong> <strong>Cancer</strong> <strong>Therapy</strong> <strong>Market</strong>: Regional Estimates & Trend<br />
<strong>Analysis</strong>, By Product<br />
Chapter 6 Competitive L<strong>and</strong>scape<br />
Browse More Medical Devices Related <strong>Market</strong> Research Reports:<br />
• Intraocular Lens (IOL) <strong>Market</strong> <strong>Analysis</strong> <strong>and</strong> Segment Forecasts, <strong>2014</strong>-<strong>2025</strong> -<br />
http://www.hexareports.com/report/<strong>in</strong>traocular-lenses-market<br />
• Res<strong>to</strong>rative Dentistry <strong>Market</strong> <strong>Analysis</strong> <strong>and</strong> Segment Forecasts, <strong>2014</strong>-<strong>2025</strong> -<br />
http://www.hexareports.com/report/res<strong>to</strong>rative-dentistry-market<br />
Follow Us:
About Us:<br />
Hexa Reports is a market research <strong>and</strong> consult<strong>in</strong>g organization, offer<strong>in</strong>g <strong>in</strong>dustry reports,<br />
cus<strong>to</strong>m research <strong>and</strong> consult<strong>in</strong>g services <strong>to</strong> a host of key <strong>in</strong>dustries across the globe. We offer<br />
comprehensive bus<strong>in</strong>ess <strong>in</strong>telligence <strong>in</strong> the form of <strong>in</strong>dustry reports which help our clients<br />
obta<strong>in</strong> clarity about their bus<strong>in</strong>ess environment <strong>and</strong> enable them <strong>to</strong> undertake strategic growth<br />
<strong>in</strong>itiatives.<br />
Contact Information:<br />
Ryan Shaw<br />
Fel<strong>to</strong>n Office Plaza,<br />
6265 Highway 9,<br />
Fel<strong>to</strong>n, California, 95018,<br />
United States<br />
Phone Number<br />
1-800-489-3075<br />
Email Us: sales@hexareports.com<br />
Our Website: http://www.hexareports.com/<br />
Follow Us:
Change language